NSTG - NanoString Technologies, Inc.
| Previous Close | 21.71 |
| Open | 21.83 |
| Bid | 21.53 x 1400 |
| Ask | 21.99 x 800 |
| Day's Range | 21.59 - 22.00 |
| 52 Week Range | 13.26 - 34.78 |
| Volume | 4,332 |
| Avg. Volume | 526,906 |
| Market Cap | 772.679M |
| Beta (3Y Monthly) | 1.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.50 |
| Earnings Date | Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.50 |
- Business Wire
NanoString to Release Third Quarter 2019 Financial Results and Host Conference Call on Monday, November 4, 2019
NanoString Technologies, Inc. (NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release third quarter 2019 financial results after the close of trading on Monday, November 4, 2019. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update. Individuals interested in listening to the conference call may do so by dialing (866) 211-0364 for domestic callers, or (647) 689-6861 for international callers.
- Business Wire
NanoString Reports Inducement Grant Under NASDAQ Listing Rules
NanoString Technologies, Inc. (NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported, as required by NASDAQ Stock Market Rules, an equity inducement award to Mark Winham, the Company’s new Senior Vice President, Operations. In accordance with NASDAQ Listing Rule 5635(c)(4), NanoString's Board of Directors approved the grant of the following equity award to Mr. Winham as a material inducement to Mr. Winham entering into employment with NanoString: effective as of the date his employment with NanoString began, a stock option to purchase 50,000 shares of the company's common stock.
- Business Wire
NanoString Appoints Mark Winham Senior Vice President of Operations
NanoString Technologies, Inc. (NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the appointment of Mark Winham as senior vice president of Operations effective October 2, 2019. Mr. Winham worked for more than ten years in manufacturing for Applied Biosystems and Life Technologies, serving in positions of escalating responsibility from senior director to vice president of Global Manufacturing. As vice president of Global Manufacturing, Mr. Winham was responsible for more than 40 manufacturing sites worldwide that included over 2500 employees.
- GlobeNewswire
CareDx Adds HistoMap To Testing Portfolio
CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced a strategic partnership with NanoString to develop HistoMap, a gene expression profiling (GEP) solution to identify allograft rejection in transplant biopsy tissue. Seattle-based NanoString (NSTG) is a leading provider of life science tools for translational research and molecular diagnostic products.
- Business Wire
NanoString Introduces New Gene Expression Research Panel for Human Organ Transplantation
NanoString Technologies, Inc. (NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the launch of a new gene expression panel for researchers to evaluate the human immune response following organ transplantation. The new nCounter® Human Organ Transplant panel has been created through a collaboration between NanoString and the Banff Foundation for Allograft Pathology (https://banfffoundation.org/), a global consortium of 6 leading transplant institutes including, University of Alberta, Erasmus Medical Center Rotterdam, Imperial College London, Massachusetts General Hospital, University of Oxford and the Paris Transplant Group, and Descartes University contributed to the design of the panel.
- Simply Wall St.
The NanoString Technologies (NASDAQ:NSTG) Share Price Has Gained 87% And Shareholders Are Hoping For More
It hasn't been the best quarter for NanoString Technologies, Inc. (NASDAQ:NSTG) shareholders, since the share price...
- GlobeNewswire
NanoString to Present at the 2019 Morgan Stanley Global Healthcare Conference
SEATTLE, Aug. 28, 2019 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products,.
- Thomson Reuters StreetEvents
Edited Transcript of NSTG earnings conference call or presentation 31-Jul-19 8:30pm GMT
Q2 2019 NanoString Technologies Inc Earnings Call
- GlobeNewswire
NanoString to Present at the Baird 2019 Global Healthcare Conference
SEATTLE, Aug. 19, 2019 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products,.
- GuruFocus.com
Nanostring Technologies Inc (NSTG) President and CEO R Bradley Gray Sold $993,600 of Shares
President and CEO of Nanostring Technologies Inc (30-Year Financial, Insider Trades) R Bradley Gray (insider trades) sold 40,000 shares of NSTG on 08/12/2019 at an average price of $24.84 a share. Continue reading...
- GuruFocus.com
Nanostring Technologies Inc (NSTG) CFO K Thomas Bailey Sold $899,175 of Shares
CFO of Nanostring Technologies Inc (30-Year Financial, Insider Trades) K Thomas Bailey (insider trades) sold 35,625 shares of NSTG on 08/06/2019 at an average price of $25.24 a share. Continue reading...
- GlobeNewswire
New Publication Demonstrates First Use of NanoString’s GeoMx Digital Spatial Profiler in Neuroscience
NanoString Technologies, Inc. (NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the publication of a study in the journal Acta Neuropathologica that demonstrates the capability of the GeoMx™ Digital Spatial Profiler (DSP) to characterize the microenvironment surrounding beta-Amyloid plaques in the brains of Alzheimer’s disease (AD) patients.
- Motley Fool
NanoString Technologies Delivers 21% Revenue Growth in Q2
All eyes were on a new instrument launch, which got off to a strong start judging from pre-orders.
Motley FoolNanostring Technologies (NSTG) Q2 2019 Earnings Call Transcript
NSTG earnings call for the period ending June 30, 2019.
- Zacks
NanoString Technologies (NSTG) Reports Q2 Loss, Tops Revenue Estimates
NanoString (NSTG) delivered earnings and revenue surprises of -3.64% and 4.64%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
NanoString Technologies Releases Operating Results for Second Quarter of 2019
SEATTLE, July 31, 2019 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today.
- GlobeNewswire
NanoString Technologies and Mayo Clinic Laboratories Enter Joint Development Agreement to Develop Novel Assays
SEATTLE and ROCHESTER, Minn., July 30, 2019 -- NanoString Technologies and Mayo Clinic Laboratories have announced a collaboration to develop clinical tests using NanoString's.
- Zacks
Will NanoString Technologies (NSTG) Report Negative Earnings Next Week? What You Should Know
NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
CORRECTING and REPLACING - Nature Medicine Publication Highlights use of the GeoMx Digital Spatial Profiler to Characterize Mechanism of Neurotoxicity in Immuno-Therapy
In a release issued yesterday by NanoString Technologies, Inc. (NSTG) under the same headline, please note that in the third paragraph Dr. Justin Balko's title has been revised. While checkpoint inhibitors can lead to durable responses in a range of metastatic cancers, unanticipated immune-related adverse events can limit the utility of these life-saving therapies.
- Simply Wall St.
Is NanoString Technologies, Inc. (NASDAQ:NSTG) A Financially Sound Company?
Investors are always looking for growth in small-cap stocks like NanoString Technologies, Inc. (NASDAQ:NSTG), with a...
- GlobeNewswire
Nature Medicine Publication Highlights use of the GeoMx Digital Spatial Profiler to Characterize Mechanism of Neurotoxicity in Immuno-Therapy
While checkpoint inhibitors can lead to durable responses in a range of metastatic cancers, unanticipated immune-related adverse events can limit the utility of these life-saving therapies. A group of researchers lead by Dr. Justin Balko recently published a study entitled “A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor induced encephalitis.” In this case report, investigators used the GeoMx DSP to characterize immune infiltrates in the brain of a patient who passed away from neurotoxicity following immunotherapy treatment for metastatic melanoma.
- Motley Fool
What to Watch When NanoString Technologies Reports Q2 Results
Investors will be focused on a potentially trajectory-altering product launch, but it will be several quarters (at least) before we can start drawing conclusions about its impact.
- GlobeNewswire
NanoString Collaborates with MODEL-AD Consortium to Accelerate Alzheimer’s Disease Research
nCounter Mouse AD Gene Expression Panel Applied to Characterize Five Novel Mouse Models New nCounter Human AD Gene Expression Panel Launched at AAIC 2019 SEATTLE, July.
- Motley Fool
Here's Why NanoString Technologies Stock Soared 104.7% in the First Half of 2019
Investors are excited (perhaps a little too excited) about a new opportunity in immuno-oncology.
